nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—CHRM1—Secretion of Hydrochloric Acid in Parietal Cells—GAST—duodenum cancer	0.243	0.243	CbGpPWpGaD
Paroxetine—TACR1—G alpha (q) signalling events—GAST—duodenum cancer	0.0434	0.0434	CbGpPWpGaD
Paroxetine—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—GAST—duodenum cancer	0.0388	0.0388	CbGpPWpGaD
Paroxetine—TACR1—SIDS Susceptibility Pathways—SST—duodenum cancer	0.0344	0.0344	CbGpPWpGaD
Paroxetine—TACR1—Peptide ligand-binding receptors—SST—duodenum cancer	0.0294	0.0294	CbGpPWpGaD
Paroxetine—TACR1—GPCR ligand binding—SCT—duodenum cancer	0.0207	0.0207	CbGpPWpGaD
Paroxetine—TACR1—Class A/1 (Rhodopsin-like receptors)—SST—duodenum cancer	0.0197	0.0197	CbGpPWpGaD
Paroxetine—CHRM5—G alpha (q) signalling events—GAST—duodenum cancer	0.0191	0.0191	CbGpPWpGaD
Paroxetine—SLC6A4—SIDS Susceptibility Pathways—SST—duodenum cancer	0.0178	0.0178	CbGpPWpGaD
Paroxetine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—GAST—duodenum cancer	0.0171	0.0171	CbGpPWpGaD
Paroxetine—TACR1—GPCR ligand binding—SST—duodenum cancer	0.015	0.015	CbGpPWpGaD
Paroxetine—HTR2A—G alpha (q) signalling events—GAST—duodenum cancer	0.0135	0.0135	CbGpPWpGaD
Paroxetine—CHRM1—G alpha (q) signalling events—GAST—duodenum cancer	0.0134	0.0134	CbGpPWpGaD
Paroxetine—CHRM3—G alpha (q) signalling events—GAST—duodenum cancer	0.0134	0.0134	CbGpPWpGaD
Paroxetine—TACR1—GPCR downstream signaling—GAST—duodenum cancer	0.0124	0.0124	CbGpPWpGaD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—GAST—duodenum cancer	0.0121	0.0121	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—GAST—duodenum cancer	0.012	0.012	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—GAST—duodenum cancer	0.012	0.012	CbGpPWpGaD
Paroxetine—TACR1—GPCR downstream signaling—SCT—duodenum cancer	0.0117	0.0117	CbGpPWpGaD
Paroxetine—CHRM4—G alpha (i) signalling events—SST—duodenum cancer	0.0114	0.0114	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—GAST—duodenum cancer	0.0112	0.0112	CbGpPWpGaD
Paroxetine—HTR2A—SIDS Susceptibility Pathways—SST—duodenum cancer	0.0107	0.0107	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—SCT—duodenum cancer	0.0106	0.0106	CbGpPWpGaD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—SST—duodenum cancer	0.0105	0.0105	CbGpPWpGaD
Paroxetine—CHRM4—GPCR ligand binding—SCT—duodenum cancer	0.00952	0.00952	CbGpPWpGaD
Paroxetine—CHRM5—GPCR ligand binding—SCT—duodenum cancer	0.00912	0.00912	CbGpPWpGaD
Paroxetine—CHRM4—Class A/1 (Rhodopsin-like receptors)—SST—duodenum cancer	0.00904	0.00904	CbGpPWpGaD
Paroxetine—CHRM5—Class A/1 (Rhodopsin-like receptors)—SST—duodenum cancer	0.00866	0.00866	CbGpPWpGaD
Paroxetine—TACR1—GPCR downstream signaling—SST—duodenum cancer	0.00847	0.00847	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—SST—duodenum cancer	0.00769	0.00769	CbGpPWpGaD
Paroxetine—CHRM2—G alpha (i) signalling events—SST—duodenum cancer	0.00757	0.00757	CbGpPWpGaD
Paroxetine—CHRM4—GPCR ligand binding—SST—duodenum cancer	0.00688	0.00688	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—GAST—duodenum cancer	0.00663	0.00663	CbGpPWpGaD
Paroxetine—CHRM5—GPCR ligand binding—SST—duodenum cancer	0.00659	0.00659	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—SCT—duodenum cancer	0.00645	0.00645	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—SCT—duodenum cancer	0.00642	0.00642	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—SCT—duodenum cancer	0.0064	0.0064	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—SCT—duodenum cancer	0.00634	0.00634	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—SCT—duodenum cancer	0.00629	0.00629	CbGpPWpGaD
Paroxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—SST—duodenum cancer	0.00613	0.00613	CbGpPWpGaD
Paroxetine—CHRM1—Class A/1 (Rhodopsin-like receptors)—SST—duodenum cancer	0.0061	0.0061	CbGpPWpGaD
Paroxetine—CHRM3—Class A/1 (Rhodopsin-like receptors)—SST—duodenum cancer	0.00608	0.00608	CbGpPWpGaD
Paroxetine—CHRM2—Class A/1 (Rhodopsin-like receptors)—SST—duodenum cancer	0.00602	0.00602	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—GAST—duodenum cancer	0.00568	0.00568	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—MEN1—duodenum cancer	0.00549	0.00549	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—GAST—duodenum cancer	0.00544	0.00544	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—SCT—duodenum cancer	0.00538	0.00538	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—GAST—duodenum cancer	0.00515	0.00515	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—SCT—duodenum cancer	0.00515	0.00515	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—GAST—duodenum cancer	0.00494	0.00494	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—SCT—duodenum cancer	0.00489	0.00489	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—SCT—duodenum cancer	0.00468	0.00468	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—SST—duodenum cancer	0.00467	0.00467	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—SST—duodenum cancer	0.00464	0.00464	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—SST—duodenum cancer	0.00463	0.00463	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—SST—duodenum cancer	0.00458	0.00458	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—SST—duodenum cancer	0.00455	0.00455	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—SST—duodenum cancer	0.00389	0.00389	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—GAST—duodenum cancer	0.00385	0.00385	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—GAST—duodenum cancer	0.00383	0.00383	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—GAST—duodenum cancer	0.00382	0.00382	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—GAST—duodenum cancer	0.00378	0.00378	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—SST—duodenum cancer	0.00373	0.00373	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—SCT—duodenum cancer	0.00365	0.00365	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—SCT—duodenum cancer	0.00363	0.00363	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—SCT—duodenum cancer	0.00362	0.00362	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—SCT—duodenum cancer	0.00358	0.00358	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—SST—duodenum cancer	0.00353	0.00353	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—GAST—duodenum cancer	0.00349	0.00349	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—GAST—duodenum cancer	0.00348	0.00348	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—GAST—duodenum cancer	0.00346	0.00346	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—GAST—duodenum cancer	0.00343	0.00343	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—SST—duodenum cancer	0.00338	0.00338	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—SCT—duodenum cancer	0.00331	0.00331	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—SCT—duodenum cancer	0.00329	0.00329	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—SCT—duodenum cancer	0.00328	0.00328	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—SCT—duodenum cancer	0.00325	0.00325	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—GAST—duodenum cancer	0.00304	0.00304	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—GAST—duodenum cancer	0.00292	0.00292	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—SCT—duodenum cancer	0.00289	0.00289	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SCT—duodenum cancer	0.00276	0.00276	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—SST—duodenum cancer	0.00264	0.00264	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—SST—duodenum cancer	0.00262	0.00262	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—SST—duodenum cancer	0.00261	0.00261	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—SST—duodenum cancer	0.00259	0.00259	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MEN1—duodenum cancer	0.00252	0.00252	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MEN1—duodenum cancer	0.00242	0.00242	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—SST—duodenum cancer	0.00239	0.00239	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—SST—duodenum cancer	0.00238	0.00238	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—SST—duodenum cancer	0.00237	0.00237	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—SST—duodenum cancer	0.00235	0.00235	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—SST—duodenum cancer	0.00209	0.00209	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—GAST—duodenum cancer	0.00206	0.00206	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—GAST—duodenum cancer	0.00205	0.00205	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—GAST—duodenum cancer	0.00205	0.00205	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—GAST—duodenum cancer	0.00203	0.00203	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SST—duodenum cancer	0.002	0.002	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SCT—duodenum cancer	0.00196	0.00196	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SCT—duodenum cancer	0.00195	0.00195	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SCT—duodenum cancer	0.00194	0.00194	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SCT—duodenum cancer	0.00192	0.00192	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MEN1—duodenum cancer	0.00171	0.00171	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MEN1—duodenum cancer	0.0017	0.0017	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MEN1—duodenum cancer	0.0017	0.0017	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MEN1—duodenum cancer	0.00168	0.00168	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SST—duodenum cancer	0.00141	0.00141	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SST—duodenum cancer	0.00141	0.00141	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SST—duodenum cancer	0.0014	0.0014	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SST—duodenum cancer	0.00139	0.00139	CbGpPWpGaD
